Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE (DD-MM-YYYY)
01-08-2008
REPORT TYPE
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES14. ABSTRACT The main goal of this work was to test and further develop a hypothesis that structural modifications and/or interference between two heterochromatin proteins: MNEI and HP1 lead to abnormal gene regulation and impaired myeloid differentiation, CML acceleration, blast crises and/or secondary acute leukemia. In specific aim 1, we separated monomeric and high molecular forms of MNEI by chromatography and gel electrophoresis and probed their primary structure by mass spectroscopy and Western blotting indicating the presence of MNEI-elastase complex also containing an unmodified peptide specific for the high molecular form. We raised antibodies against 3 distinct high molecular forms of MNEI. We found that these antibodies recognize elevated levels of high molecular MNEI co-expressed with HP1 in a subset of CML cases including blastic form of CML. In specific Aim 2 we constructed cell lines derived from a blastic CML cell model K562 expressing MNEI and HP1. We showed that expression of MNEI did not interfere with constitutive heterochromatin but significantly inhibited cell proliferation. Using high throughput gene expression analysis and chromatin immunoprecipitation, we found that HP1 and MNEI similarly target multiple chromosomal loci. Our results suggest that MNEI interacts with chromosomal loci vacated by HP1 during normal myeloid differentiation and that association with the same set of gene targets with HP1 may impair gene regulation in cases where both MNEI isoforms and HP1 are expressed.
SUBJECT TERMS